Compare MASS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASS | EOLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.1M | 500.0M |
| IPO Year | 2020 | 2018 |
| Metric | MASS | EOLS |
|---|---|---|
| Price | $12.85 | $7.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $13.38 | ★ $15.00 |
| AVG Volume (30 Days) | 356.5K | ★ 669.0K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.47 | 1.23 |
| EPS | N/A | ★ N/A |
| Revenue | $56,197,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $22.97 | $12.44 |
| Revenue Next Year | $19.41 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $5.03 | $3.86 |
| 52 Week High | $13.35 | $9.31 |
| Indicator | MASS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 51.57 |
| Support Level | $6.06 | $7.59 |
| Resistance Level | $13.35 | $7.83 |
| Average True Range (ATR) | 0.58 | 0.32 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 88.83 | 79.57 |
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.